Publications by authors named "S Nicum"
Background: Ethnic and socioeconomic disparities in cancer outcomes are exacerbated by clinical trial underrepresentation. This study aims to identify inequalities in ethnicity and socioeconomic features among ovarian cancer clinical trial participants in two London cancer centres.
Methods: All ovarian cancer patients treated between 2017 and 2022 were included.
Aims: Patients with endometrial cancer who progress following first line therapy have improved survival outcomes with pembrolizumab and lenvatinib (pem/len) compared with standard of care chemotherapy, as demonstrated in KEYNOTE-775. This was in a group of trial patients with good performance status and excluded those with carcinosarcoma histology. In KEYNOTE-775 pem/len was associated with significant toxicity, leading to dose reductions, treatment cessation, and patient morbidity.
View Article and Find Full Text PDFArticle Synopsis
- The guidelines are created by the British Gynaecological Cancer Society and British Menopause Society to help healthcare professionals support women treated for gynaecological cancer, especially regarding menopausal symptoms that can affect life quality.* -
- Cancer treatments like surgery, radiotherapy, and chemotherapy can impact hormonal function, and the guidelines discuss the use of hormone replacement therapy (HRT) based on cancer type and when it should start post-treatment.* -
- The document also highlights the effectiveness and safety of vaginal estrogens for urogenital symptoms and reviews alternative treatments to HRT, including both medication and lifestyle approaches.*
Introduction: Chemotherapy forms the cornerstone of systemic treatment for advanced ovarian cancer, extending overall survival; however, drug-related toxicity can lead to treatment delays, potentially diminishing treatment efficacy. This study evaluated the impact of treatment delays on all-cause mortality of patients with ovarian cancer, to better inform decisions on patient management.
Methods: This retrospective, population-based cohort study included 1517 women with advanced-stage ovarian cancer, receiving first-line adjuvant or neoadjuvant chemotherapy in 2014 and 2015.
Objective: Underrepresentation of elderly ovarian cancer patients in clinical trials has led to lack of clarity regarding optimal first-line chemotherapy in this cohort. The Elderly Women with Ovarian Cancer (EWOC)-1 trial demonstrated that 3-weekly carboplatin (3wC) resulted in worse survival and feasibility compared with standard 3-weekly carboplatin-paclitaxel (3wCP) in frail, elderly ovarian cancer patients. Our retrospective study compares feasibility, safety, and efficacy of first-line 3wCP and 3wC in a frail ovarian cancer cohort.
View Article and Find Full Text PDF